After Class 12, students interested in Artificial Intelligence can choose from several education paths — short 1-year ...
Research and Development Expenses -- $9.6 million in the third quarter of 2025, down from $12.3 million in Q3 2024, due to ...
Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding ...
Biogen  Inc. (Nasdaq: BIIB) – will present new data from its felzartamab clinical development programs at Kidney Week 2025, the American Society of Nephrology’s (ASN) annual meeting, taking place ...
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ...